Browsing by Author Thavaneswaran, Subotheni

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2016ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Day, Fiona; Desai, Jayesh; Elez, Elena; et al, Various; Jefford, Michael; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours, BMC Cancer, vol.16, 1, 2016,pp 1-8
2016Optimal therapy for resectable rectal cancerPrice, Timothy; Thavaneswaran, Subotheni; NH&MRC Clinical Trials CentreOptimal therapy for resectable rectal cancer, Expert Review of Anticancer Therapy, vol.16, 3, 2016,pp 285-302
2016Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyGebski, Val; Khasraw, Mustafa; Pavlakis, Nick; Robledo, Kristy; Simes, Robert John; Thavaneswaran, Subotheni; Wilson, Kate; Chantrill, Lorraine A; Desai, Jayesh; Elez, Elena; et al, Various; Karapetis, Christos (Chris); Lunke, Sebastian; Nott, Louise M; Segelov, Eva; Underhill, Craig; Waring, Paul; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; School of Molecular Bioscience (SMB)Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study, Journal of Clinical Oncology, vol.34, 19, 2016,pp 2258-2264
2016Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Gibbs, Peter; Thavaneswaran, Subotheni; Arnold, Dirk; Burge, Matthew; Haller, Daniel; Karapetis, Christos; Pavlakis, Nick; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreUpdate on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015, Expert Review of Anticancer Therapy, vol.16, 5, 2016,pp 557-571
2016Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015Gibbs, Peter; Thavaneswaran, Subotheni; Arnold, Dirk; Burge, Matthew; Haller, Daniel; Karapetis, Christos; Pavlakis, Nick; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreUpdate on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015, Expert Review of Anticancer Therapy, vol.16, 5, 2016,pp 557-571